Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CHRS

CHRS - Coherus Biosciences Inc Stock Price, Fair Value and News

$2.21-0.30 (-11.95%)
Market Closed

29/100

CHRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

29/100

CHRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.65

Target 3M

$1.92

Target 6M

$1.78

CHRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CHRS Price Action

Last 7 days

34.8%

Last 30 days

64.9%

Last 90 days

30%

Trailing 12 Months

99.1%

CHRS RSI Chart

CHRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CHRS Valuation

Market Cap

267.1M

Price/Earnings (Trailing)

1.72

Price/Sales (Trailing)

7.19

EV/EBITDA

-0.96

Price/Free Cashflow

-2.96

CHRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.65

Target 3M

$1.92

Target 6M

$1.78

CHRS Fundamentals

CHRS Revenue

Revenue (TTM)

37.2M

Rev. Growth (Yr)

91.19%

Rev. Growth (Qtr)

12.84%

CHRS Earnings

Earnings (TTM)

155.0M

Earnings Growth (Yr)

-230.49%

Earnings Growth (Qtr)

-111.93%

CHRS Profitability

EBT Margin

-490.56%

Return on Equity

176.56%

Return on Assets

30%

Free Cashflow Yield

-33.76%

CHRS Investor Care

Shares Dilution (1Y)

4.91%

Diluted EPS (TTM)

1.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202531.7M31.6M37.2M0
2024137.2M100.3M63.3M26.4M
2023183.4M181.9M211.1M174.1M
2022303.6M276.1M239.1M211.0M
2021442.7M394.6M363.6M326.6M
2020435.1M487.4M489.3M475.8M
2019284.9M308.6M332.3M356.1M
20170213.8M237.5M261.2M
201636.6M43.8M199.5M190.1M
201533.3M35.2M26.3M30.0M
20145.8M10.3M25.8M31.1M
20132.1M2.3M2.5M2.8M
20120001.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Coherus Biosciences Inc

CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
 CEO
 WEBSITEcoherus.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES294

Coherus Biosciences Inc Frequently Asked Questions

CHRS is the stock ticker symbol of Coherus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Coherus Biosciences Inc is 267.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CHRS's fair value in chart for subscribers.

The fair value guage provides a quick view whether CHRS is over valued or under valued. Whether Coherus Biosciences Inc is cheap or expensive depends on the assumptions which impact Coherus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CHRS.

As of Wed Jan 28 2026, CHRS's PE ratio (Price to Earnings) is 1.72 and Price to Sales (PS) ratio is 7.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CHRS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Coherus Biosciences Inc has provided -0.164 (multiply by 100 for percentage) rate of return.